ArticleCalcified tissue international2026
Clinical Characteristics, Treatment Patterns, and Complications in Permanent Hypoparathyroidism: A Large Retrospective Cross-Sectional Study.
Article in Calcified tissue international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to evaluate treatment patterns, complications, and associated risk factors in a large cohort of patients with permanent hypoparathyroidism (HypoPT). This retrospective cross-sectional study included 958 adults with permanent HypoPT. Clinical and laboratory features were compared by etiology: postsurgical (86.4%) and nonsurgical (13.6%). The surgical group was further stratified by benign versus malignant thyroid histopathology. Risk factors for HypoPT-related complications were assessed using regression analyses. Patients received calcium, calcitriol, thiazide diuretics, cholecalciferol, teriparatide, or palopegteriparatide. Nephrolithiasis/nephrocalcinosis, basal ganglia calcifications (BGC), cataract, and hypercalciuria were detected in 13.5, 15.2, 20.8, and 44.4%, respectively, intravenous (IV) calcium was required in 8.4% within two years. Compared with postsurgical group, nonsurgical patients had lower calcium and parathyroid hormone (PTH), higher phosphate levels, greater calcium and calcitriol requirements, higher rates of BGC and IV calcium requirement, and higher T-scores (p < 0.05); nephrolithiasis/nephrocalcinosis and cataract were also more frequent (p = 0.086 and 0.072). Compared with malignant histopathology, benign group was associated with a higher BGC prevalence and higher phosphate levels (p = 0.022 and < 0.001). Hypercalciuria was independently associated with nephrolithiasis/nephrocalcinosis; older age, nonsurgical etiology, longer disease duration, hyperphosphatemia, and undetectable PTH with BGC; nonsurgical etiology with cataract; younger age, treatment suboptimal-adherence, and absence of hypercalciuria with IV calcium requirement (p < 0.05). Additionally, in univariable analyses, high-dose calcitriol was associated with nephrolithiasis/nephrocalcinosis and high-dose calcium with BGC (p < 0.05). In conclusion, HypoPT-related complications were associated with hyperphosphatemia, hypercalciuria, undetectable PTH, and high-dose conventional treatment, underscoring the need for better treatments and future studies to determine whether PTH-replacement therapy reduces complication risks.
Indexed as
Identifiers
42435057What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.